Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PAH drug-device developer SteadyMed prices IPO

This article was originally published in Scrip

Executive Summary

Israeli firm SteadyMed, which is developing a drug-device combination product for the treatment of pulmonary arterial hypertension (PAH), has priced its IPO – but raised less than expected. The firm pulled in $40m by selling 4.7 million shares at $8.50, below the $12-14 range it gave when it set terms in March. It also falls short of the $55m it said it was targeting in a filing with the US Securities and Exchange Commission in February. SteadyMed's Trevyent device, which uses its PatchPump technology, is prefilled with treprostinil, which it claims is the only parenteral drug for PAH approved by the US FDA for both intravenous and subcutaneous administration. The single-use pump, which itself is still investigational and not yet approved by the FDA, delivers the drug over two days. It is also equipped with sensors to give patients feedback on successful delivery and end of dosing, the company says.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts